PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. – UroToday

PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. UroToday Clearance of non-tumor-bound tracer is predominantly renal and widely completed by 48h. Safety dosimetry reveals kidney doses of approx. 0.75 Gy/GBq, red-marrow 0.03 Gy/GBq, salivary glands 1.4 Gy/GBq; irrespective of tumor burden and consistent on … and more »

from #ORL-AlexandrosSfakianakis via simeraentaxei on Inoreader http://ift.tt/1RtCGIx
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1RaxRAx
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1SbJuYb
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1XFChkx
via IFTTT